The pharmaceutical industry in Bangladesh is facing a critical juncture, with a regulatory deadlock over drug pricing threatening to stifle innovation and patient access to life-saving therapies. This crisis, now in its second year, has left hundreds of new medicines stranded, impacting both the industry and the population's healthcare outcomes.
The heart of the issue lies in the Directorate General of Drug Administration's (DGDA) inability to fix prices for new medicines, a process that has been delayed for months. This delay is not just a bureaucratic hurdle but a significant barrier to progress. Pharmaceutical companies, including Healthcare Pharmaceuticals and Beximco Pharmaceuticals, have developed and manufactured products, only to be left in limbo due to the lack of price approval.
The situation is particularly dire for patients, as the delay means they are denied access to newer treatments for various serious illnesses, including cancer, diabetes, and chronic kidney disease. The industry estimates that over 100 drug manufacturers are waiting for marketing approval and price fixation for thousands of medicines, a backlog that is causing widespread concern.
The crisis has intensified following a High Court order last August, which directed the government to determine the prices of all life-saving medicines. This order, filed by the Consumer Association of Bangladesh (CAB), has effectively stopped the DGDA from fixing prices for new medicines, creating a two-tier healthcare system where only those who can afford imported medicines have access to the latest treatments.
The impact of this regulatory impasse is far-reaching. Industry executives warn that it is slowing innovation and preventing patients from accessing newer therapies already available in other parts of the world. The delay is also tying up large investments, with top 20 to 25 pharmaceutical companies each having 20 to 30 products awaiting approval, while smaller manufacturers face similar backlogs.
The situation is further complicated by the fact that even price reductions are on hold. ACI Pharmaceuticals, for instance, applied to reduce the price of TirzepatideINN 2.5mg/0.5mL, a treatment for Type 2 diabetes, but their application remains pending despite repeated follow-ups. This inability to pass on price reductions due to the current pricing framework is a significant challenge for local manufacturers.
DGDA officials acknowledge the problem but cite legal hurdles as the primary cause of the delay. They say the pricing mechanism is governed by Section 30 of the Drugs and Cosmetics Act, 2023, but the process has been inoperative due to political changes and the lack of a fully reconstituted Drug Control Committee, which is responsible for granting final approval for new medicines.
The regulatory deadlock comes at a critical time for Bangladesh's pharmaceutical industry, which is highly competitive globally and meets about 98% of domestic demand. With the country preparing to graduate from least developed country status in 2026, when many intellectual property flexibilities for generic medicines will disappear, regulatory certainty has become even more crucial.
In conclusion, the drug pricing deadlock in Bangladesh is a complex issue that requires urgent attention. The government must resolve the regulatory impasse and clear the backlog of pending applications to ensure that patients have access to the latest and most effective treatments. The industry's survival and the country's global competitiveness depend on it.
